Citius Pharma Analyst Ratings
Citius Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 296.59% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 08/01/2023 | 296.59% | HC Wainwright & Co. | $6 → $4 | Maintains | Buy |
| 05/30/2023 | 494.88% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/03/2023 | 494.88% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/29/2023 | 494.88% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/18/2022 | 494.88% | HC Wainwright & Co. | $4 → $6 | Maintains | Buy |
| 11/30/2021 | 296.59% | Maxim Group | → $4 | Initiates Coverage On | → Buy |
| 02/07/2019 | 197.44% | HC Wainwright & Co. | → $3 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月10日 | 296.59% | HC Wainwright公司 | →$4 | 重申 | 購買→購買 |
| 08/01/2023 | 296.59% | HC Wainwright公司 | $6→$4 | 維護 | 買 |
| 2023年05月30日 | 494.88% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 04/03/2023 | 494.88% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 03/29/2023 | 494.88% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 01/18/2022 | 494.88% | HC Wainwright公司 | $4→$6 | 維護 | 買 |
| 2021年11月30日 | 296.59% | Maxim集團 | →$4 | 開始承保 | →購買 |
| 2019年07月02日 | 197.44% | HC Wainwright公司 | →$3 | 假設 | →購買 |
What is the target price for Citius Pharma (CTXR)?
花旗製藥(Citius Pharma)的目標價是多少？
The latest price target for Citius Pharma (NASDAQ: CTXR) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $4.00 expecting CTXR to rise to within 12 months (a possible 296.59% upside). 5 analyst firms have reported ratings in the last year.
花旗製藥(納斯達克代碼：CTXR)的最新目標價是由HC Wainwright&Co.於2023年8月10日報道的。這家分析公司將目標價定為4美元，預計CTXR將在12個月內升至(可能上漲296.59%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Citius Pharma (CTXR)?
分析師對花旗製藥(Citius Pharma)的最新評級是多少？
The latest analyst rating for Citius Pharma (NASDAQ: CTXR) was provided by HC Wainwright & Co., and Citius Pharma reiterated their buy rating.
花旗製藥(納斯達克代碼：CTXR)的最新分析師評級由HC Wainwright&Co.提供，花旗製藥重申其買入評級。
When is the next analyst rating going to be posted or updated for Citius Pharma (CTXR)?
花旗製藥(Citius Pharma)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharma was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與花旗製藥的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Citius Pharma的上一次評級是在2023年8月10日提交的，所以你應該預計下一次評級將在2024年8月10日左右的某個時候公佈。
Is the Analyst Rating Citius Pharma (CTXR) correct?
分析師對花旗製藥(Citius Pharma)的評級正確嗎？
While ratings are subjective and will change, the latest Citius Pharma (CTXR) rating was a reiterated with a price target of $0.00 to $4.00. The current price Citius Pharma (CTXR) is trading at is $1.01, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但花旗製藥(Citius Pharma)的最新評級被重申為A，目標價在0.00美元至4.00美元之間。花旗製藥(Citius Pharma)目前的交易價格為1.01美元，在分析師的預測範圍內。